Philogen SpA reported a significant increase in cash reserves in the first half of 2026, with cash and cash equivalents topping EUR 300 million. This figure represents a substantial rise from EUR 100 million in H1 2025 and EUR 64 million in H1 2024. The company's financial performance also included an EBITDA loss of approximately EUR 20 million for the period.
The stock trading details at the time of reporting showed a trading price of $22.65, up 2.03% from the prior close of $22.20. The 52-week range for the stock was below a high of $26 and above a low of $19.56, representing a 12.9% decrease from its high and a 15.8% increase from its low.
Philogen SpA, based in Siena, Italy, has a strong pipeline of products and clinical trials. The company has filed an EMA submission for Nidlegy, a treatment for melanoma and non-melanoma skin cancer, on July 23, 2026. The company expects to receive feedback from Europe regarding the EMA submission in November or December 2026.
In the field of oncology, Philogen is developing Fibromun, a treatment for soft tissue sarcoma and glioblastoma. The FIBROSARC trial showed an overall survival improvement from 13.6 months to 21 months in a subgroup representing 70% of the study population. The FIBROSARC US trial is enrolling 87 out of 158 patients with metastatic leiomyosarcoma.
The company also has a number of other clinical trials in progress, including DUNCAN-2, a first-line basal cell carcinoma trial, and NeoDREAM, a trial for glioblastoma. Philogen expects to complete the U.S. trial for NeoDREAM in 2028, with 184 of the 240 planned patients enrolled at the time of presentation.
Dario Neri, the Chief Executive Officer of Philogen, expressed confidence in the company's cash situation and its ability to manage operating costs. He also highlighted the importance of in-house capabilities for moving products to development and the company's commitment to providing clinical proof of principle.
Philogen SpA is a biopharmaceutical company focused on the development and commercialization of innovative therapies. The company's pipeline includes a range of products targeting various medical conditions, including cancer, autoimmune diseases, and infectious diseases. Philogen has a strong presence in Europe and the United States, with operations in Siena, Milan, and Zurich.
